Healthcare companies by risk reading
Healthcare companies by risk reading: 1,693 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 20 October 2026.
Composite readings for 14,891 companies, recomputed 20 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Zenas Biopharma Inc ZBIO | 68 | Stretched | Healthcare | United States | 4 / 6 | $1.7B |
| Personalis Inc PSNL | 54 | Elevated | Healthcare | United States | 6 / 6 | $1.7B |
| DENTSPLY Sirona Inc XRAY | 57 | Elevated | Healthcare | United States | 5 / 6 | $1.7B |
| Consun Pharmaceutical Group Limited 1681.HK | 21 | Normal | Healthcare | China | 5 / 6 | $1.7B |
| UroGen Pharma Ltd URGN | 66 | Stretched | Healthcare | United States | 6 / 6 | $1.7B |
| ANI Pharmaceuticals Inc ANIP | 51 | Elevated | Healthcare | United States | 5 / 6 | $1.7B |
| Septerna Inc SEPN | 36 | Normal | Healthcare | United States | 5 / 6 | $1.7B |
| Ardent Health Partners Inc ARDT | 55 | Elevated | Healthcare | United States | 5 / 6 | $1.7B |
| Omnicell Inc OMCL | 68 | Stretched | Healthcare | United States | 6 / 6 | $1.6B |
| REDCARE PHARMACY NV RDC | 50 | Elevated | Healthcare | Netherlands | 3 / 6 | $1.6B |
| Fujian Haixi Pharmaceuticals Co., Ltd. 2637.HK | 29 | Normal | Healthcare | China | 4 / 6 | $1.6B |
| Intellia Therapeutics Inc NTLA | 46 | Elevated | Healthcare | United States | 5 / 6 | $1.6B |
| Sonida Senior Living Inc SNDA | 62 | Stretched | Healthcare | United States | 4 / 6 | $1.6B |
| Generate Biomedicines, Inc. GENB | 53 | Elevated | Healthcare | United States | 5 / 6 | $1.6B |
| 4DMEDICAL Ltd 4DX | 45 | Elevated | Healthcare | Australia | 4 / 6 | $1.6B |
| Phibro Animal Health Corp - Class A PAHC | 40 | Elevated | Healthcare | United States | 6 / 6 | $1.6B |
| Alphatec Holdings Inc ATEC | 73 | Stretched | Healthcare | United States | 5 / 6 | $1.6B |
| JMDC Inc. 4483.T | 24 | Normal | Healthcare | Japan | 5 / 6 | $1.6B |
| AMN Healthcare Services Inc AMN | 54 | Elevated | Healthcare | United States | 5 / 6 | $1.6B |
| Nuvation Bio Inc - Class A NUVB | 63 | Stretched | Healthcare | United States | 5 / 6 | $1.6B |
| Aevis Victoria SA AEVS | 61 | Stretched | Healthcare | Switzerland | 5 / 6 | $1.6B |
| Ping An Healthcare and Technology Company Limited 1833.HK | 54 | Elevated | Healthcare | China | 5 / 6 | $1.6B |
| Stoke Therapeutics Inc STOK | 27 | Normal | Healthcare | United States | 5 / 6 | $1.5B |
| Nolato AB (publ) NOLA-B | 48 | Elevated | Healthcare | Sweden | 4 / 6 | $1.5B |
| uniQure N.V. QURE | 76 | Stretched | Healthcare | Netherlands | 5 / 6 | $1.5B |
| Immunocore Holdings plc IMCR | 36 | Normal | Healthcare | United Kingdom | 6 / 6 | $1.5B |
| Innoviva Inc INVA | 33 | Normal | Healthcare | United States | 5 / 6 | $1.5B |
| Mesoblast Ltd MESO | 42 | Elevated | Healthcare | Australia | 4 / 6 | $1.5B |
| Azenta Inc AZTA | 53 | Elevated | Healthcare | United States | 6 / 6 | $1.5B |
| Shenzhen Edge Medical Co., Ltd. 2675.HK | 54 | Elevated | Healthcare | China | 5 / 6 | $1.5B |
| Agilon Health Inc AGL | 43 | Elevated | Healthcare | United States | 5 / 6 | $1.5B |
| ChemoMetec A/S CHEMM | 27 | Normal | Healthcare | Denmark | 5 / 6 | $1.5B |
| Ultragenyx Pharmaceutical Inc RARE | 47 | Elevated | Healthcare | United States | 6 / 6 | $1.5B |
| Nakanishi Inc. 7716.T | 30 | Normal | Healthcare | Japan | 5 / 6 | $1.5B |
| Bonesupport Holding AB BONEX | 33 | Normal | Healthcare | Sweden | 3 / 6 | $1.5B |
| Nippon Shinyaku Co., Ltd. 4516.T | 37 | Normal | Healthcare | Japan | 5 / 6 | $1.5B |
| Ship Healthcare Holdings, Inc. 3360.T | 42 | Elevated | Healthcare | Japan | 5 / 6 | $1.5B |
| Absci Corp ABSI | 73 | Stretched | Healthcare | United States | 4 / 6 | $1.5B |
| AnaptysBio Inc ANAB | 21 | Normal | Healthcare | United States | 4 / 6 | $1.5B |
| Everest Medicines Limited 1952.HK | 43 | Elevated | Healthcare | China | 5 / 6 | $1.5B |
| Pacira BioSciences Inc PCRX | 49 | Elevated | Healthcare | United States | 5 / 6 | $1.4B |
| Certara Inc CERT | 58 | Elevated | Healthcare | United States | 5 / 6 | $1.4B |
| NAKANISHI INC. 6SN | 34 | Normal | Healthcare | Japan | 5 / 6 | $1.4B |
| Healthcare Services Group Inc HCSG | 36 | Normal | Healthcare | United States | 6 / 6 | $1.4B |
| Ascentage Pharma Group International AAPG | 54 | Elevated | Healthcare | China | 5 / 6 | $1.4B |
| Nipro Corporation 8086.T | 43 | Elevated | Healthcare | Japan | 5 / 6 | $1.4B |
| Pennant Group Inc PNTG | 32 | Normal | Healthcare | United States | 5 / 6 | $1.4B |
| SMS Co., Ltd. 2175.T | 39 | Normal | Healthcare | Japan | 5 / 6 | $1.4B |
| MicroPort Scientific Corporation MSK | 63 | Stretched | Healthcare | China | 5 / 6 | $1.4B |
| Eton Pharmaceuticals Inc ETON | 32 | Normal | Healthcare | United States | 5 / 6 | $1.4B |
| Ocular Therapeutix Inc OCUL | 71 | Stretched | Healthcare | United States | 6 / 6 | $1.4B |
| Conmed Corp CNMD | 48 | Elevated | Healthcare | United States | 6 / 6 | $1.4B |
| Spire Healthcare Group plc S00 | 45 | Elevated | Healthcare | United Kingdom | 5 / 6 | $1.4B |
| GenFleet Therapeutics (Shanghai) Inc. 2595.HK | 52 | Elevated | Healthcare | China | 5 / 6 | $1.4B |
| Clariane SE CLARI | 47 | Elevated | Healthcare | France | 6 / 6 | $1.3B |
| Spire Healthcare Group Plc SPI | 46 | Elevated | Healthcare | United Kingdom | 5 / 6 | $1.3B |
| Inhibrx Biosciences Inc INBX | 63 | Stretched | Healthcare | United States | 5 / 6 | $1.3B |
| Nutex Health Inc NUTX | 10 | Contained | Healthcare | United States | 4 / 6 | $1.3B |
| Create SD Holdings Co., Ltd. 3148.T | 41 | Elevated | Healthcare | Japan | 5 / 6 | $1.3B |
| Taysha Gene Therapies Inc TSHA | 51 | Elevated | Healthcare | United States | 5 / 6 | $1.3B |
| Medartis Holding AG MED.SW | 48 | Elevated | Healthcare | Switzerland | 5 / 6 | $1.3B |
| H.U. Group Holdings, Inc. 4544.T | 47 | Elevated | Healthcare | Japan | 5 / 6 | $1.3B |
| PHC HOLDINGS CORP. 2GY | 51 | Elevated | Healthcare | Japan | 4 / 6 | $1.3B |
| Ain Holdings Inc. 9627.T | 40 | Elevated | Healthcare | Japan | 5 / 6 | $1.3B |
| U.S. Physical Therapy Inc USPH | 35 | Normal | Healthcare | United States | 5 / 6 | $1.3B |
| Nektar Therapeutics NKTR | 74 | Stretched | Healthcare | United States | 6 / 6 | $1.3B |
| Ramsay Générale de Santé SA GDS.PA | 53 | Elevated | Healthcare | France | 5 / 6 | $1.2B |
| GNI Group Ltd. 2160.T | 68 | Stretched | Healthcare | Japan | 5 / 6 | $1.2B |
| COSMO Pharmaceuticals SA COPN | 65 | Stretched | Healthcare | Ireland | 5 / 6 | $1.2B |
| Sawai Group Holdings Co., Ltd. 4887.T | 50 | Elevated | Healthcare | Japan | 5 / 6 | $1.2B |
| NANOBIOTIX NANO.PA | 80 | Acute | Healthcare | France | 4 / 6 | $1.2B |
| InnovAge Holding Corp INNV | 42 | Elevated | Healthcare | United States | 5 / 6 | $1.2B |
| Cronos Group Inc CRON | 54 | Elevated | Healthcare | Canada | 5 / 6 | $1.2B |
| Opko Health Inc OPK | 63 | Stretched | Healthcare | United States | 6 / 6 | $1.2B |
| AS ONE Corporation 7476.T | 38 | Normal | Healthcare | Japan | 5 / 6 | $1.2B |
| Raffles Medical Group Ltd BSL.SI | 44 | Elevated | Healthcare | Singapore | 5 / 6 | $1.2B |
| Avanos Medical Inc AVNS | 73 | Stretched | Healthcare | United States | 4 / 6 | $1.2B |
| Syndax Pharmaceuticals Inc SNDX | 59 | Elevated | Healthcare | United States | 5 / 6 | $1.2B |
| UNIPHAR PLC UPR.IR | 43 | Elevated | Healthcare | Ireland | 5 / 6 | $1.2B |
| GoodRx Holdings Inc - Class A GDRX | 52 | Elevated | Healthcare | United States | 4 / 6 | $1.1B |
| Enovis Corp ENOV | 69 | Stretched | Healthcare | United States | 5 / 6 | $1.1B |
| Towa Pharmaceutical Co., Ltd. 4553.T | 41 | Elevated | Healthcare | Japan | 5 / 6 | $1.1B |
| Akso Health Group AHG | 87 | Acute | Healthcare | China | 4 / 6 | $1.1B |
| Tandem Diabetes Care Inc TNDM | 73 | Stretched | Healthcare | United States | 5 / 6 | $1.1B |
| Iradimed Corp IRMD | 40 | Elevated | Healthcare | United States | 6 / 6 | $1.1B |
| Amphastar Pharmaceuticals Inc AMPH | 51 | Elevated | Healthcare | United States | 6 / 6 | $1.1B |
| PHC Holdings Corporation 6523.T | 50 | Elevated | Healthcare | Japan | 5 / 6 | $1.1B |
| Shanghai INT Medical Instruments Co., Ltd. 1501.HK | 30 | Normal | Healthcare | China | 5 / 6 | $1.1B |
| Staar Surgical Company STAA | 89 | Acute | Healthcare | United States | 4 / 6 | $1.1B |
| Omada Health Inc OMDA | 45 | Elevated | Healthcare | United States | 6 / 6 | $1.1B |
| Suzhou Ribo Life Science Co., Ltd. 6938.HK | 72 | Stretched | Healthcare | China | 5 / 6 | $1.1B |
| HBM Holdings Limited 2142.HK | 12 | Contained | Healthcare | China | 5 / 6 | $1.1B |
| Artivion Inc AORT | 49 | Elevated | Healthcare | United States | 6 / 6 | $1.1B |
| Nanobiotix NBTX | 80 | Acute | Healthcare | France | 4 / 6 | $1.1B |
| CVS Group Plc CVSG | 45 | Elevated | Healthcare | United Kingdom | 5 / 6 | $1.1B |
| CureVac N.V. CVAC | 11 | Contained | Healthcare | Germany | 5 / 6 | $1.0B |
| Procept BioRobotics Corp PRCT | 58 | Elevated | Healthcare | United States | 6 / 6 | $1.0B |
| Integra Lifesciences Holdings Corp IART | 83 | Acute | Healthcare | United States | 5 / 6 | $1.0B |
| Teladoc Health Inc TDOC | 70 | Stretched | Healthcare | United States | 5 / 6 | $1.0B |
| Maravai LifeSciences Holdings Inc - Class A MRVI | 70 | Stretched | Healthcare | United States | 5 / 6 | $1.0B |
By sector
Industrials 3,114Technology 2,425Consumer Cyclical 2,231Healthcare 1,693Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 955Energy 485Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.